兽用整形外科生物製药市场－全球产业规模、份额、趋势、机会及预测（按产品、动物、应用、给药途径、最终用户、地区和竞争格局划分，2021-2031年）

全球兽用整形外科生物製药市场预计将从 2025 年的 7.8727 亿美元成长到 2031 年的 13.1236 亿美元，复合年增长率达到 8.89%。

兽用整形外科生物製药包括干细胞、富血小板血浆和宠物饲主越来越愿意为高端医疗服务付费。对先进医疗干预的需求得到了该行业巨额支出的支持。根据美国宠物用品协会 (APPA) 预测，到 2024 年，美国兽用及相关产品的销售额预计将达到 398 亿美元，凸显了支持再生医学发展的经济投入。

然而，这些疗法的高昂费用是市场面临的重大障碍。许多整形外科材料手术对普通宠物饲主来说仍然难以负担，而且某些地区缺乏针对再生医学的全面保险覆盖，进一步限制了其普及。因此，这些经济限制构成了一项重大挑战，有可能限制这些解决方案的广泛应用，并减缓市场整体成长势头。

市场驱动因素

宠物肌肉骨骼和整形外科疾病的日益增多，尤其是宠物肥胖率的上升，是推动市场扩张的主要因素。伴侣动物体重过重会增加关节的机械压力，导致骨关节炎和韧带损伤的发生率上升，需要再生医学介入。根据宠物肥胖预防协会于2025年4月发布的《2024年宠物肥胖和营养意见调查》，35%的狗主饲主33%的猫饲主认为他们的宠物超重或肥胖，这一比例逐年上升，令人担忧。这种与体重相关的健康问题日益增多的趋势，与对骨生物疗法（例如干细胞和富血小板血浆（PRP））的激增需求直接相关，这些疗法能够有效治疗慢性关节劣化。

同时，宠物人性化的趋势正在从根本上改变兽医行业的经济格局。饲主越来越将宠物视为家庭成员，并愿意承担复杂且昂贵的医疗费用，以确保宠物的寿命和生活品质。根据美国宠物用品协会于2025年3月发布的《2025年产业趋势报告》，宠物饲养量将显着成长，目前已有9,400万个家庭至少拥有一隻宠物。这一不断成长且热衷于宠物饲主的群体，为持续投资新型再生医学技术创造了必要的市场规模。例如，Gallant Therapeutics公司于2025年7月获得了1,800万美元的B轮资金筹措，用于加速其现成干细胞疗法的商业化，凸显了市场对兽医整形外科生物製药未来发展的强劲信心。

市场挑战

高昂的治疗费用是限制兽医整形外科生物製药领域扩张的主要障碍。这些再生疗法通常涉及复杂的手术和专业应用，由此产生的高昂费用通常会直接转嫁给宠物饲主。由于许多主要市场的兽医诊所主要计量型，这些高额的自付费用实际上使普通消费者难以负担治疗费用。这种经济现实有效地将目标市场限制在富裕宠物饲主这个狭窄群体中，阻碍了推动产业快速成长所需的手术量。

宠物保险普及率低加剧了这种经济障碍，因为宠物保险无法弥补大多数家庭在医疗费用上的负担。缺乏全面的保障来抵销这些费用，使得宠物保险市场难以从小众市场过渡到大众市场。根据北美宠物健康保险协会（NAPHIA）预测，到2025年，北美投保宠物总数将达到703万隻。这一数字表明，大多数饲主缺乏足够的经济保障来支付昂贵的再生医疗手术费用，这直接限制了市场规模和收入成长。

市场趋势

市场正经历着向异体「即用型」干细胞疗法的显着转变，这主要源于对扩充性、标准化治疗方法常见发炎性疾病的迫切需求。与需要手术采集和处理的自体疗法相比，这些预製疗法可即时使用，剂量稳定，满足了全科医疗的大量临床需求。这种需求也得到了需要复杂介入的难治性疾病的强力支撑。根据2025年7月DVM360发表的报导《兽医干细胞疗法获得1800万美元资金筹措，预计获得FDA核准》，仅难治性猫慢性龈口炎就影响高达26%的家猫，这为这些新型的即用型再生医学解决方案创造了巨大的潜在市场。

同时，再生医学在马匹竞技领域的应用也日益显着，骨生物製药正逐渐成为治疗运动障碍的标准通讯协定。高价值竞技马匹需要快速有效的肌腱和韧带损伤復健策略，而专业兽医中心正将这些治疗方法纳入其核心服务，以延长马匹的竞技生涯。为了展示这一日益增长的行业应用率， 精英于2025年10月发布的新闻稿《特赖恩马医院完成超过200例VetStem再生医学病例》指出，一家大型马匹专科转诊中心已成功完成超过200例再生医学手术，这表明再生治疗方法在马匹领域正获得更广泛的认可，并商业性可行性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球动物整形外科生物製药市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（干细胞、富血小板血浆（PRP）、其他）
  • 依动物种类（狗、马、其他）
  • 依应用领域（骨关节炎、退化性关节疾病等）
  • 依给药途径（肌肉内/病灶内注射、关节内注射、其他）
  • 依最终使用者（兽医院、动物诊所等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美动物整形外科生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲动物整形外科生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区动物整形外科生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲动物整形外科生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲动物整形外科生物製药市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球动物整形外科生物製药市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Services LLC
• Boehringer Ingelheim International GmbH
• Ardent Animal Health
• Enso Discoveries, LLC
• VetStem, Inc
• MEDREGO LLC
• Arthrex, Inc.
• Hilltop Biosciences
• Enovis Corporation
• Dechra Pharmaceuticals Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Veterinary Orthobiologics Market is projected to expand from USD 787.27 Million in 2025 to USD 1312.36 Million by 2031, achieving a CAGR of 8.89%. Veterinary orthobiologics encompass biological substances like stem cells, platelet-rich plasma, and bone grafts, which veterinarians use to regenerate tissue and repair injured tendons, ligaments, and bones. The market's growth is primarily fueled by the increasing prevalence of osteoarthritis in aging companion animals and a growing willingness among pet owners to pay for premium healthcare services. This demand for advanced medical intervention is evidenced by significant industry expenditure; according to the American Pet Products Association, sales for veterinary care and products in the United States hit 39.8 billion dollars in 2024, highlighting the financial commitment supporting the adoption of regenerative therapies.

However, the market faces a substantial hurdle regarding the high costs associated with these treatments. Many orthobiologic procedures remain financially out of reach for the average pet owner, and the scarcity of comprehensive insurance coverage for regenerative therapies in specific regions further restricts accessibility. Consequently, these financial constraints constitute a major challenge that could limit the widespread implementation of these solutions and decelerate the overall momentum of market growth.

Market Driver

The escalating prevalence of veterinary musculoskeletal and orthopedic disorders, significantly worsened by rising rates of pet obesity, acts as a primary catalyst for market expansion. As companion animals carry excess weight, mechanical stress on their joints increases, resulting in a higher frequency of osteoarthritis and ligament injuries that necessitate regenerative interventions. Data from the Association for Pet Obesity Prevention's '2024 Pet Obesity & Nutrition Opinion Survey', released in April 2025, indicates that 35% of dog owners and 33% of cat owners classified their pets as overweight or obese, representing a troubling year-over-year rise. This upward trend in weight-related health issues directly correlates with the surging demand for orthobiologic therapies, such as stem cells and platelet-rich plasma, which provide effective management for chronic joint deterioration.

Concurrently, the growing trend of pet humanization is fundamentally transforming the economic landscape of veterinary care. Owners increasingly regard their pets as essential family members, fueling a willingness to pursue advanced, frequently expensive medical treatments to ensure longevity and quality of life. The American Pet Products Association's '2025 State of the Industry Report', published in March 2025, reveals that pet ownership has broadened significantly, with 94 million U.S. households now owning at least one pet. This expanding base of dedicated owners creates the necessary market scale for sustained investment in novel regenerative technologies. Illustrating this rapid sector innovation, Gallant Therapeutics secured 18 million dollars in Series B funding in July 2025 to hasten the commercialization of its off-the-shelf stem cell therapies, underscoring strong financial confidence in the future of veterinary orthobiologics.

Market Challenge

The prohibitive cost of treatment represents a major obstacle to the expansion of the veterinary orthobiologics sector. These regenerative therapies frequently entail complex processing and specialized application, leading to high prices that are generally passed directly to the pet owner. Because veterinary healthcare in many primary markets operates predominantly on a fee-for-service basis, these significant out-of-pocket expenses often make such options inaccessible to the average client. This financial reality effectively confines the addressable market to a narrow demographic of affluent pet owners, preventing the procedure volume required to drive rapid industry growth.

This economic barrier is severely aggravated by the limited penetration of pet health insurance, which fails to bridge the affordability gap for most households. Without comprehensive coverage to offset these expenses, the market struggles to transition from niche usage to mass adoption. According to the North American Pet Health Insurance Association, the total number of insured pets in North America reached 7.03 million in 2025. This figure suggests that the vast majority of owners lack the financial safety net needed to fund premium regenerative procedures, directly dampening market volume and revenue velocity.

Market Trends

The market is observing a significant Shift Toward Allogeneic "Off-the-Shelf" Stem Cell Therapies, propelled by the urgent requirement for scalable, standardized treatments for common inflammatory diseases. In contrast to autologous methods that necessitate surgical extraction and processing, these manufactured therapies provide immediate availability and consistent dosing, meeting high-volume clinical needs in general practice. This demand is heavily underscored by the prevalence of difficult-to-treat conditions requiring advanced intervention; according to a July 2025 DVM360 article titled 'Veterinary stem cell therapy advances toward FDA approval with $18M in funding', refractory feline chronic gingivostomatitis alone affects up to 26% of domestic cats, creating a substantial addressable market for these novel, ready-to-use regenerative solutions.

Simultaneously, there is a distinct Expansion of Regenerative Medicine in Equine Sports Performance, where orthobiologics are becoming standard protocols for managing athletic injuries. High-value performance horses demand rapid, effective recovery strategies for tendon and ligament issues, prompting specialized veterinary centers to integrate these therapies into their core services to prolong competitive careers. Highlighting this increasing adoption rate within elite facilities, a VetStem press release from October 2025 titled 'Tryon Equine Hospital Surpasses 200 VetStem Regenerative Medicine Cases' noted that a single leading equine referral center successfully completed over 200 regenerative procedures, signaling broader industry acceptance and the commercial viability of these treatments in the equine sector.

Key Market Players

• Zoetis Services LLC
• Boehringer Ingelheim International GmbH
• Ardent Animal Health
• Enso Discoveries, LLC
• VetStem, Inc
• MEDREGO LLC
• Arthrex, Inc.
• Hilltop Biosciences
• Enovis Corporation
• Dechra Pharmaceuticals Limited

Report Scope

In this report, the Global Veterinary Orthobiologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Orthobiologics Market, By Product

• Stem Cells
• Platelet-rich Plasma (PRP)
• Other

Veterinary Orthobiologics Market, By Animal

• Canine
• Equine
• Others

Veterinary Orthobiologics Market, By Application

• Osteoarthritis
• Degenerative Joint Disease
• Other

Veterinary Orthobiologics Market, By Delivery Mode

• Intra-muscular/Intra-lesional
• Intra-articular
• Others

Veterinary Orthobiologics Market, By End User

• Veterinary Hospitals
• Veterinary Clinics
• Others

Veterinary Orthobiologics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Orthobiologics Market.

Available Customizations:

Global Veterinary Orthobiologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Orthobiologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Stem Cells, Platelet-rich Plasma (PRP), Other)
  • 5.2.2. By Animal (Canine, Equine, Others)
  • 5.2.3. By Application (Osteoarthritis, Degenerative Joint Disease, Other)
  • 5.2.4. By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others)
  • 5.2.5. By End User (Veterinary Hospitals, Veterinary Clinics, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Orthobiologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Animal
  • 6.2.3. By Application
  • 6.2.4. By Delivery Mode
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Orthobiologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Animal
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Delivery Mode
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Veterinary Orthobiologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Animal
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Delivery Mode
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Veterinary Orthobiologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Animal
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Delivery Mode
      • 6.3.3.2.5. By End User

7. Europe Veterinary Orthobiologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Animal
  • 7.2.3. By Application
  • 7.2.4. By Delivery Mode
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Orthobiologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Animal
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Delivery Mode
      • 7.3.1.2.5. By End User
  • 7.3.2. France Veterinary Orthobiologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Animal
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Delivery Mode
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Veterinary Orthobiologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Animal
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Delivery Mode
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Veterinary Orthobiologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Animal
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Delivery Mode
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Veterinary Orthobiologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Animal
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Delivery Mode
      • 7.3.5.2.5. By End User

8. Asia Pacific Veterinary Orthobiologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Animal
  • 8.2.3. By Application
  • 8.2.4. By Delivery Mode
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Orthobiologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Animal
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Delivery Mode
      • 8.3.1.2.5. By End User
  • 8.3.2. India Veterinary Orthobiologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Animal
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Delivery Mode
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Veterinary Orthobiologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Animal
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Delivery Mode
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Veterinary Orthobiologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Animal
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Delivery Mode
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Veterinary Orthobiologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Animal
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Delivery Mode
      • 8.3.5.2.5. By End User

9. Middle East & Africa Veterinary Orthobiologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Animal
  • 9.2.3. By Application
  • 9.2.4. By Delivery Mode
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Orthobiologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Animal
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Delivery Mode
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Veterinary Orthobiologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Animal
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Delivery Mode
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Veterinary Orthobiologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Animal
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Delivery Mode
      • 9.3.3.2.5. By End User

10. South America Veterinary Orthobiologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Animal
  • 10.2.3. By Application
  • 10.2.4. By Delivery Mode
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Orthobiologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Animal
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Delivery Mode
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Veterinary Orthobiologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Animal
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Delivery Mode
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Veterinary Orthobiologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Animal
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Delivery Mode
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Orthobiologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Services LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Boehringer Ingelheim International GmbH
• 15.3. Ardent Animal Health
• 15.4. Enso Discoveries, LLC
• 15.5. VetStem, Inc
• 15.6. MEDREGO LLC
• 15.7. Arthrex, Inc.
• 15.8. Hilltop Biosciences
• 15.9. Enovis Corporation
• 15.10. Dechra Pharmaceuticals Limited

16. Strategic Recommendations

17. About Us & Disclaimer